Breaking News Instant updates and real-time market news.

AAPL

Apple

$270.71

5.15 (1.94%)

, BAC

Bank of America

$33.67

0.57 (1.72%)

08:55
12/09/19
12/09
08:55
12/09/19
08:55

Notable open interest changes for December 9th

Friday's total option volume of 20.4 million contracts resulted in net open interest growth of 2.53 million calls and 2.62 million puts. Apple (AAPL), Bank of America (BAC), Bristol Myers Squibb (BMY) and Danaher (DHR) saw the greatest growth. Top five new positions opened include 28k Southwestern Energy (SWN) Jan-20 2 puts, 26k Danaher (DHR) Dec-19 170 puts, 26k Danaher (DHR) Dec-19 170 calls, 18k Apple (AAPL) 12/13 weekly 270 calls and 17k Uber (UBER) 1/10 weekly 25 puts.

AAPL

Apple

$270.71

5.15 (1.94%)

BAC

Bank of America

$33.67

0.57 (1.72%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

DHR

Danaher

$148.17

1.1 (0.75%)

  • 09

    Dec

  • 11

    Dec

  • 15

    Jan

  • 26

    Feb

AAPL Apple
$270.71

5.15 (1.94%)

12/04/19
MAXM
12/04/19
NO CHANGE
Target $190
MAXM
Sell
Maxim says Apple to miss Q2 revenue guidance based on lower iPhone retention
Maxim analyst Nehal Chokshi is keeping his Sell rating and $190 price target on Apple, saying his proprietary survey data shows a "concerning rise of outflux" of iPhone users to 9% from 5%. The declining retention rate indicates that Q2 revenue could miss the current consensus view by about 7%, Chokshi contends. The analyst further cites the rise in China nationalism posing a risk for Apple.
12/05/19
SBSH
12/05/19
NO CHANGE
Target $300
SBSH
Buy
Apple price target raised to $300 from $250 at Citi
Citi analyst Jim Suva raised his price target for Apple to $300 from $250 after "materially" increasing his sales and earnings estimates. The analyst keeps a Buy rating on the shares, which closed Wednesday up $2.29 to $261.74. Suva models sales for the December quarter of $89.5B, above the consensus estimate of $87.9B, and earnings per share of 4.58, above the consensus of $4.51. Looking beyond the December quarter, he's also "materially above" consensus for sales and earnings and believes consensus numbers will be moving higher. Suva does not see valuation multiple expansion for Apple, noting the valuation multiple has already expanded materially, but he does see sales and earnings upside. The consensus is underappreciating the Apple Watch and AirPods demand strength as well as Apple's wearables segment, which is likely to surpass $10B of quarterly sales this quarter, Suva tells investors in a research note. He agrees with consensus that generally believes Apple's services will continue to grow and help margins, but thinks consensus is overlooking the wearable's segment.
12/06/19
LOOP
12/06/19
NO CHANGE
Target $265
LOOP
Hold
Apple price target raised to $265 from $250 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on Apple to $265, reflecting "incremental iPhone momentum". The analyst is positive on 2020 and the December quarter after the company's "updated build plans" indicated positioning of the supply chain for iPhone12 5G launch next September and the attractive camera/pricing features of iPhone 11. The analyst still keeps his Hold rating on Apple shares, with the stock trading at its recent peak earnings multiple of about 20-times.
12/09/19
CHRS
12/09/19
INITIATION
Target $342
CHRS
Buy
Apple initiated with a Buy at China Renaissance
China Renaissance analyst Jason Sun initiated coverage of Apple with a Buy rating and $342 price target. The analyst is "doubtful" about the upside potential of the iPhone but he still expects the segment to continue to be a "cash cow" given Apple's leading position in the high-end market. In addition, he expects the iPad and Mac segments revenue generation to be stable. Further, wearables and services products provide Apple with a "new revenue injection," Sun tells investors in a research note.
BAC Bank of America
$33.67

0.57 (1.72%)

10/29/19
SOCG
10/29/19
DOWNGRADE
SOCG
Sell
Bank of America downgraded to Sell from Hold at Societe Generale
Societe Generale analyst Andrew Lim downgraded Bank of America to Sell from Hold.
10/28/19
10/28/19
UPGRADE

Buy
Bank of America upgraded to Buy from Hold at Odeon Capital
As previously reported, Odeon Capital analyst Dick Bove upgraded Bank of America to Buy from Hold. Bove called the stock "a good investment," noting Bank of America's growth from a company "struggling to maintain its existence" to a large, stable one, although not the growth vehicle it once was. The analyst sees a revenue growth rate of 3.3% per year from now to 2025, net income that could grow at 4.9%, and earnings per share that could grow at 6.5%. He believes the increased confidence in Bank of America stock is driven by the company's balance sheet strength and its decision to base future growth on "internally generated revenues and earnings." Bove believes as long as it can "maintain reasonable loan quality its future earnings and dividend growth lends itself to a relatively high level of predictability."
10/28/19
ODEN
10/28/19
UPGRADE
ODEN
Buy
Bank of America upgraded to Buy from Hold at Odeon Capital
Odeon Capital analyst Dick Bove upgraded Bank of America to Buy from Hold.
10/22/19
10/22/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Discovery (DISCA) upgraded to Outperform from In-Line at Imperial Capital with analyst David Miller sayign amidst changes in the Media sector, and against "various levels of turmoil" within many of the company's peers, Discovery has emerged "as one of the cleaner stories in the sector." 2. Dropbox (DBX) upgraded to Buy from Neutral at Nomura Instinet with analyst Christopher Eberle saying the company is nearing an inflection in revenue after six quarters of deceleration as a public company and its current valuation is attractive. 3. Workday (WDAY) and Anaplan (PLAN) upgraded to Outperform from In Line at Evercore ISI. 4. Owens Corning (OC) upgraded to Buy from Neutral at Buckingham with analyst Megan McGrath saying the company's installation business should benefit from recent improved volumes in residential U.S. construction and potentially improved price stability. 5. Bank of America (BAC) upgraded to Overweight from Neutral at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$59.94

0.435 (0.73%)

12/08/19
PIPR
12/08/19
NO CHANGE
PIPR
Piper says Bluebird's bb2121 'clearly approvable,' but competition heating up
Piper Jaffray analyst Tyler Van Buren said the topline results presented by Bluebird Bio (BLUE) at ASH from the KarMMa trial are "impressive in these very sick patients" and he believes that the drug is "clearly approvable." However, he also said that the JNJ-4528 Legend data presented by Johnson & Johnson's (JNJ) Janssen "appears very competitive," adding that "we would be remiss if we didn't mention the continued deluge of anti-BCMA antibody data" from competitors including Amgen (AMGN), Bristol-Myers (BMY) and Regeneron (REGN). Van Buren keeps a Neutral rating on Bluebird Bio shares, citing valuation as well as his view on long-term competitive pressures.
12/03/19
MSCO
12/03/19
NO CHANGE
Target $100
MSCO
Equal Weight
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
Morgan Stanley analyst Matthew Harrison said he sees a high probability, or 75% odds, that Bluebird Bio (BLUE) shares will trade higher following the report of topline results from its KarMMa study of bb2121 as a fourth line or later therapy for the treatment of relapsed/refractory multiple myeloma, which are due by year-end. He said investors are focused on the median progression free survival delivered by the therapy as a gauge of its commercial viability versus other anti-BCMA CAR-T therapies in development at GlaxoSmithKline (GSK) and Bristol-Myers (BMY) in partnership with Regeneron (REGN). In a scenario where median PFS is greater than or equal to 11.5 months and overall response rate is greater than or equal to 85%, Harrison sees Bluebird shares having 20%-30% or more upside. If the median PFS is equal to or less than 9 months and ORR is below 80%, he thinks bb2121 would likely still be approvable, but sees shares down 10%-20%. In what he views as the most likely scenario - with mPFS of about 10 months and ORR of about 80% - Harrison sees 10%-20% upside in Bluebird shares. He keeps an Equal Weight rating and $100 price target on the stock.
11/27/19
11/27/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Vonage (VG) initiated with a Neutral at JPMorgan. 2. Bristol-Myers Squibb CVR (BMY-R, BMY) initiated with a Buy at Gabelli. 3. Novus Therapeutics (NVUS) initiated with a Buy at H.C. Wainwright. 4. KushCo Holdings (KSHB) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/09/19
MZHO
12/09/19
NO CHANGE
Target $3.99
MZHO
Buy
Bristol-Myers Squibb CVR price target raised to $3.99 from $3.14 at Mizuho
Mizuho analyst Salim Syed raised his price target for the Bristol-Myers Squibb CVR (BMR-R) to $3.99 from $3.14 after attending the company's investor event. In addition to the bb2121 data Friday and JCAR017 data Saturday, the Bristol-Myers (BMY) investor event "was clean," Syed tells investors in a research note. The analyst says the weekend was probably the "best or near-best" CVR outcome.
DHR Danaher
$148.17

1.1 (0.75%)

10/14/19
FBCO
10/14/19
INITIATION
Target $151
FBCO
Outperform
Danaher reinstated with an Outperform at Credit Suisse
Credit Suisse analyst Erin Wilson Wright reinstated coverage of Danaher with an Outperform rating and $151 price target. The analyst likes the company's increasing exposure to "faster-growing" end markets like biopharma given its pending acquisition of GE's BioPharma business and the spin-off of Envista Holdings. Further, Danaher continues to expand its exposure to recurring revenue streams, adds the analyst.
10/14/19
JEFF
10/14/19
INITIATION
Target $34
JEFF
Buy
Envista initiated with a Buy at Jefferies
Jefferies analyst Brandon Couillard initiated coverage of Envista (NVST) with a Buy rating and $34 price target. Envista is emerging from a three-year turnaround inside Danaher (DHR) as a much stronger stand-alone company, well positioned for improved growth and margin expansion, Couillard tells investors in a research note. He finds the stock's current valuation as compelling.
10/14/19
MSCO
10/14/19
INITIATION
Target $29
MSCO
Equal Weight
Envista initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lewis initiated coverage of Envista (NVST), a spinoff of Danaher's (DHR) Dental segment, with an Equal Weight rating and $29 price target. Growth slowed from 2% to flat and margins compressed over the past three years as the company invested in innovation and while channel stabilization and new product launches provide a path to accelerate growth and expand margins, he thinks the stock's current valuation reflects some acceleration, Lewis tells investors.
11/14/19
STFL
11/14/19
INITIATION
Target $150
STFL
Hold
Danaher resumed with a Hold at Stifel
Stifel analyst Daniel Arias resumed overage of Danaher with a Hold rating and $150 price target. The analyst is a "bit cautious" on the potential for deal-driven upside to not be as robust as some think in 2020.

TODAY'S FREE FLY STORIES

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.